Clinical trials
Progressive Multiple Sclerosis clinical trials
Below are recruiting progressive multiple sclerosis clinical trials, each written for real people, not researchers. We’re tracking 132 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07355387Recruiting
Home-based balance training for multiple sclerosis
This study tests a 12-week home-based balance training program for people with multiple sclerosis. Sessions are done online with a helper present, and the goal is to improve walking and reduce fall risk.
Chicago, IllinoisAges 40–90 - NCT07342777Recruiting
Exercise for Pain Relief in Multiple Sclerosis
This study tests whether exercise can help reduce pain in people with multiple sclerosis. If you have MS and moderate to severe pain, you may be asked to participate in a supervised exercise program.
Aarhus, DenmarkAges 18 years+ - NCT07325292RecruitingPhase 3
Frexalimab injection vs IV for multiple sclerosis
This study tests if a new injection (frexalimab) works as well as the IV version for people with relapsing or certain types of secondary progressive multiple sclerosis. It could offer a more convenient way to receive this treatment at home.
Cullman, AlabamaAges 18–60 - NCT07299019RecruitingPhase 3
Study of orelabrutinib for secondary progressive MS
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
Phoenix, ArizonaAges 18–60 - NCT07303790RecruitingEarly Phase 1
Study of GC012F for people with multiple sclerosis
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hubei, HubeiAges 18 years+ - NCT07282574RecruitingPhase 2
Study of an add-on drug for progressive multiple sclerosis
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
Camperdown, New South WalesAges 18–60 - NCT07222618Recruiting
Selfie videos to measure function in MS
This trial asks people with MS to record short 'selfie' videos of themselves doing everyday tasks, like walking or getting dressed. The goal is to find a better, more personal way to measure how MS affects daily function.
San Francisco, CaliforniaAges 18 years+ - NCT07225504RecruitingPhase 3
Study of remibrutinib for secondary progressive multiple sclerosis
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Birmingham, AlabamaAges 18–65 - NCT07178431RecruitingPhase 1/Phase 2
CAR T-cell therapy for worsening multiple sclerosis
This trial tests a new treatment called MB-CART2019.1, which uses your own immune cells to fight multiple sclerosis. It is for people with progressive or worsening MS who have not responded well to other treatments.
BerlinAges 18–55 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07067463RecruitingPhase 3
Testing orelabrutinib for primary progressive MS
This trial tests a daily pill called orelabrutinib to see if it can slow disability progression in people with primary progressive multiple sclerosis (PPMS). It may be an option for patients whose symptoms have been getting worse over the past two years.
Pheonix, ArizonaAges 18–60 - NCT06890923RecruitingPhase 2
Nasal foralumab for non-active secondary progressive MS
This trial tests a nasal spray medication, foralumab, to see if it can help people with non-active secondary progressive multiple sclerosis. It is only for people who completed a previous related study (TILS-021).
Boston, MassachusettsAges 18–75 - NCT03910738RecruitingPhase 2
Testosterone treatment for nerve protection and myelin repair in MS
This Phase 2 study tests whether taking testosterone (for low testosterone levels) can help protect nerves and repair myelin in people with relapsing-remitting multiple sclerosis (MS). It may be most relevant if your MS is stable and you have low blood testosterone without current androgen treatment.
BesançonAges 18–55 - NCT06864936Recruiting
Eye scan study for ublituximab in multiple sclerosis
This study uses a special eye scan (OCT) to see how well the MS medication ublituximab works. It compares people starting ublituximab to those on other stable MS treatments, to find better ways to measure treatment success.
Baltimore, MarylandAges 18–65 - NCT06495138Recruiting
Eye exercises for dizziness in multiple sclerosis
This study tests a new type of eye exercise to help with dizziness and balance problems in people with multiple sclerosis (MS). The exercise involves moving your head and eyes in a specific way to retrain your balance system.
Atlanta, GeorgiaAges 18–89 - NCT05532943RecruitingPhase 1/Phase 2
Cord stem cell treatment for people with multiple sclerosis
This Phase 1/2 trial studies whether donated umbilical cord stem cells are safe and can improve multiple sclerosis. It aims to see if the treatment is workable for people who still have active MS despite standard therapies.
Taichung, Non-USAges 20–65 - NCT06629428RecruitingEarly Phase 1
Study of ublituximab for walking and movement in multiple sclerosis
This trial tests if ublituximab can improve walking and other motor skills in people with active relapsing MS. You must be able to walk at least 25 feet and stand 30 seconds on your own.
Atlanta, GeorgiaAges 18–55 - NCT06592703RecruitingPhase 1
Stem cells for primary progressive MS
This study tests whether stem cells from donated fat tissue can slow down primary progressive multiple sclerosis. You would receive a single injection of the cells into your spinal fluid and be followed for up to 2 years.
CréteilAges 18–55 - NCT06599307RecruitingPhase 2
Rituximab for thinking and hand function in advanced MS
This trial tests whether the drug rituximab can help people with secondary progressive MS keep their thinking and hand abilities from getting worse. It is for people with more advanced disability.
Giza, Giza GovernorateAges 18 years+ - NCT06569550Recruiting
Fatigue treatment study for multiple sclerosis
This trial tests a brain stimulation therapy designed to reduce fatigue in people with multiple sclerosis. If you experience moderate to severe fatigue and have a stable medication routine, this study might help determine if a non-invasive treatment can improve your energy levels.
Hvidovre, Capital RegionAges 18–65 - NCT06526364Recruiting
Multiple sclerosis study with smartphone app tracking
This study follows people with multiple sclerosis over time using a smartphone app and clinic visits. It aims to better understand the disease and improve care.
BaselAges 18 years+ - NCT06495593Enrolling by invitationPhase 4
Ocrelizumab's effect on immune cells in lymph nodes in MS
This study tests how ocrelizumab, a medication for MS, affects immune cells in your lymph nodes. It may help doctors understand how the drug works and why it helps some people more than others.
San Francisco, CaliforniaAges 18–65 - NCT06408259RecruitingPhase 3
Comparing ozanimod and fingolimod for children with MS
This study compares two oral medications, ozanimod and fingolimod, to see which one works better and is safer for children and teenagers with relapsing-remitting MS. Both drugs help reduce MS attacks and slow down the disease.
Loma Linda, CaliforniaAges 10–17 - NCT06390930Recruiting
Breathing bursts of lower oxygen for hand function in MS
This study tests whether breathing short bursts of reduced oxygen (acute intermittent hypoxia) can improve hand function and nerve health in people with relapsing-remitting MS who have some hand weakness.
Chicago, IllinoisAges 18–75
Hear when a new Progressive Multiple Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progressive multiple sclerosis?
- Yes. Clin2 currently lists 132 recruiting progressive multiple sclerosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progressive multiple sclerosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progressive multiple sclerosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Multiple Sclerosis, Secondary Progressive
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis (MS) Primary Progressive
- Multiple Sclerosis (MS) Secondary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis (MS) - Relapsing-remitting
- Relapsing Multiple Sclerosis
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.